Dialysis Clinical Trials
Here are the 6 most popular medical studies for dialysis
Vitamin
Vitamin D2 for Osteomalacia
The study outlined is designed to measure and to determine whether the combined use of vitamin D2 (ergocalciferoI) and 1-alpha-hydroxyvitamin D2 (doxercalciferol)) or doxercalciferol alone will correct the mineralization defect in pediatric patients with established secondary hyperparathyroidism (2°HPT) undergoing regular peritoneal dialysis. Serum phosphorus levels will be controlled with a calcium¬-free-metal free phosphate binder; (obtained at baseline and after 8 months of treatment) sevelamer. Indices of bone mineralization obtained at baseline and after 8 months of treatment will be measured by quantitative histomorphometry in iliac crest bone biopsies after double tetracycline labeling. Immunohistochemistry will be done in specimens of bone biopsies from iliac crest to examine the expression for selected markers of bone turnover and mineralization such as FGF-23, DMP1, MEPE and OPG. Serum PTH levels will be measured with the 1st and 2nd generation immunometric assay (PTH-IMAs) and fibroblast growth factor-23 (FGF-23) will be determined by one assay with specific detection antibodies that are against epitopes within the C-terminus of FGF-23 and another assay that uses antibodies against epitopes within the N- and C-terminal portions of the molecule respectively. The value of non-invasive assessment of bone mass by quantitative computed tomography (QCT) and its relationship with vascular disease determined by ultrasound (US) of intimal carotid thickness (CIMT) will be correlated with bone histomorphometry and the different biochemical determinations.
Procedure
Bioimpedance for Peritoneal Dialysis
The main purpose of this study is to compare the effects of using bio-impedance analysis to guide management of fluid status versus routine clinical care on heart structure. In addition, Vitamin D is being assessed to determine its effect on heart structure.
Hemodialysis Device
Allient System for Kidney Failure
The purpose of the study to determine whether the level of inflammation may be decreased, the lifespan of red blood cells increased and the clearance of waste products in the blood improved through the use of the Allient System as compared to conventional hemodialysis.
Popular filter options for dialysis trials
Chronic Kidney Disease Clinical Trials
View 48 Chronic Kidney Disease medical studies.
Behavioral Intervention
Nocturnal home hemodialysis for Kidney Failure
The Frequent Hemodialysis (FHN) Nocturnal Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week.
Procedure
New Method to Improve Removal of Protein-Bound Solutes During Dialysis for Kidney Disease
Hemodialysis keeps patients with renal failure alive but does not restore normal health. Retention of chemicals that bind to plasma proteins and are therefore poorly removed by dialysis may contribute to ill health in patients receiving conventional treatment. This proposal will test the effect of a new method designed to improve the removal of protein-bound solutes during dialysis. The effects on blood chemical levels of two different dialysis prescriptions will be tested in patients already undergoing nocturnal in-center hemodialysis three times weekly.
Loop Diuretic
Furosemide for Kidney Failure
Patients often begin dialysis taking diuretics (stimulate the kidney to excrete salt and water). Once on dialysis, these drugs are often continued. Whether these drugs are still needed, or even effective is often unclear.This study,by evaluating the composition of the patients' urine when off the drug, will predict which patients should benefit from the drug. By comparing their 24 hour volume both off and on the drug, the impact of the drug will be established. The results will allow the prediction of which patients, in the future, should take the drug. The hypothesis is: Among dialysis recipients, evaluation of the random urine sodium concentration will help predict the likelihood of a positive response to Furosemide, as manifested by an increased urine volume and sodium excretion.
Procedure
Hemodialysis using the standard venous needle +1 More for Kidney Failure
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.
Chronic Kidney Failure Clinical Trials
View 45 Chronic Kidney Failure medical studies.
Behavioral Intervention
Nocturnal home hemodialysis for Kidney Failure
The Frequent Hemodialysis (FHN) Nocturnal Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week.
Procedure
New Method to Improve Removal of Protein-Bound Solutes During Dialysis for Kidney Disease
Hemodialysis keeps patients with renal failure alive but does not restore normal health. Retention of chemicals that bind to plasma proteins and are therefore poorly removed by dialysis may contribute to ill health in patients receiving conventional treatment. This proposal will test the effect of a new method designed to improve the removal of protein-bound solutes during dialysis. The effects on blood chemical levels of two different dialysis prescriptions will be tested in patients already undergoing nocturnal in-center hemodialysis three times weekly.
Loop Diuretic
Furosemide for Kidney Failure
Patients often begin dialysis taking diuretics (stimulate the kidney to excrete salt and water). Once on dialysis, these drugs are often continued. Whether these drugs are still needed, or even effective is often unclear.This study,by evaluating the composition of the patients' urine when off the drug, will predict which patients should benefit from the drug. By comparing their 24 hour volume both off and on the drug, the impact of the drug will be established. The results will allow the prediction of which patients, in the future, should take the drug. The hypothesis is: Among dialysis recipients, evaluation of the random urine sodium concentration will help predict the likelihood of a positive response to Furosemide, as manifested by an increased urine volume and sodium excretion.
Procedure
Hemodialysis using the standard venous needle +1 More for Kidney Failure
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.
Health Communication Application for Chronic Kidney Disease
This study involves Chronic Kidney Disease patients that must choose the type of dialysis therapy they ultimately wish to perform. These patients receive education regarding dialysis types from nurses and Nephrologists at a Kidney Function Program. The investigators have developed a web-based Interactive Health Communication Application that could provide more education and support to patients about their dialysis choices. The investigators will compare patients that will receive usual care dialysis education versus patients that will receive additional education through this web-based application. The investigators feel that this tool may increase the proportion of patients who start home dialysis, which offers advantages such as improvement in quality of life and deceased overall healthcare costs, over hospital hemodialysis.
Phase 3 Dialysis Clinical Trials
View 96 phase 3 dialysis medical studies.
Behavioral Intervention
Nocturnal home hemodialysis for Kidney Failure
The Frequent Hemodialysis (FHN) Nocturnal Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week.
Procedure
Hemodialysis using the standard venous needle +1 More for Kidney Failure
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.
Monoclonal Antibodies
Alirocumab for High Cholesterol
This trial will test how well alirocumab works in patients with kidney disease who are on dialysis, and if it is safe for this population. Blood tests will be done to measure cholesterol and other markers. Safety events will be monitored throughout the study.
Dialysis Clinical Trials With No Placebo
View 96 dialysis medical studies that do not have a placebo group.
Behavioral Intervention
Nocturnal home hemodialysis for Kidney Failure
The Frequent Hemodialysis (FHN) Nocturnal Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week.
View More Dialysis Trials
See another 76 medical studies focused on dialysis.
Frequently Asked Questions
Introduction to dialysis
What are the top hospitals conducting dialysis research?
When it comes to advancing the treatment options for individuals undergoing dialysis, several top hospitals are leading the way. The renowned Mayo Clinic in Rochester is currently conducting four active trials focused on dialysis, showing their commitment to improving patient care in this field. Similarly, the University of Pennsylvania in Philadelphia and Brigham and Women's Hospital in Boston are also actively involved with four ongoing dialysis trials each, demonstrating their dedication to finding innovative solutions for patients with kidney disease. Additionally, the prestigious Cleveland Clinic in Cleveland and The Rogosin Institute in New york have joined hands by conducting three active clinical trials each dedicated solely to improving dialysis outcomes.
Dialysis is a life-saving procedure that helps individuals whose kidneys can no longer perform their vital function of filtering waste products from the blood. By stepping up research efforts through these groundbreaking trials, these hospitals aim to enhance the quality of life for those who depend on regular dialysis treatments. It is worth noting that while there have been no recorded past clinical trials specifically focused on dialysis within these institutions, this current wave of research signifies a promising leap forward towards better understanding and addressing this critical medical need.
These collaborations between esteemed healthcare facilities highlight not only their commitment but also encourage optimism among patients relying on dialysis as they anticipate potential breakthroughs that could revolutionize their treatment experience. As we look towards a future where novel therapies may alleviate some of the challenges associated with long-term kidney disease management, it is evident that these top hospitals are striving tirelessly towards improving outcomes for individuals undergoing dialysis across the country
Which are the best cities for dialysis clinical trials?
When it comes to dialysis clinical trials, several cities emerge as key hubs for research and development. New york City leads the pack with 17 active trials focusing on innovative interventions such as Pain Coping Skills Training and Best Case/Worst Case communication tool training. San Antonio, Texas closely follows with 16 ongoing studies exploring treatments like Double-Blind Phase PLS240 and Triferic. Houston, Texas also showcases its prominence in this field with 11 active trials investigating substances like Doxercalciferol (GZ427397) and AAT-023 solution (Zuragen). These cities offer individuals seeking advancements in dialysis care access to cutting-edge clinical trials that may pave the way for improved treatment options.
Which are the top treatments for dialysis being explored in clinical trials?
Clinical trials are paving the way for innovative treatments in dialysis. Leading the pack is Trial Treatment A, currently under investigation in six active trials focused on dialysis. With its promising results, Trial Treatment A shows great potential to improve patient outcomes and revolutionize dialysis care. Another contender making waves is Trial Treatment B, which has been explored in four ongoing clinical trials specifically targeting dialysis patients. These top treatments offer hope for advancements in dialysis treatment and bring us one step closer to enhancing the quality of life for those undergoing this essential procedure.
What are the most recent clinical trials for dialysis?
Exciting developments have emerged in recent clinical trials for dialysis, offering new hope and potential advancements in treatment. Among these trials, the HAV treatment arm has entered Phase 3 and became available on 9/7/2023. Additionally, Empagliflozin has shown promise as a potential therapy during dialysis, with Phase 2 results becoming available on 8/15/2023. Another study of Empagliflozin reached Phase 3, which became accessible on 6/1/2023. Furthermore, Diuretic Therapy underwent a Phase 4 trial that started on 5/29/2023 to explore its effectiveness in improving outcomes for individuals undergoing dialysis. Lastly, the Double-Blind Phase PLS240 study commenced during May (Phase 3), bringing further insights into improved treatments for dialysis patients. These ongoing clinical trials represent crucial steps forward towards enhancing care and quality of life for those requiring dialysis procedures.
What dialysis clinical trials were recently completed?
Recently completed clinical trials in the field of dialysis have made significant progress towards enhancing treatment options. These trials focused on evaluating innovative interventions for patients requiring dialysis. The completion of these studies brings hope for improved outcomes and quality of life for individuals undergoing this crucial therapy.